DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Hortobagyi GN.
Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial.
J Clin Oncol 2014;
32: 5s (Suppl.; Abstr. LBA 9500)
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.